Facebook
X
LinkedIn
ForwardHPV-Negative Head and Neck Cancer: The Next Frontier
There are many ongoing advances in patient safety in the context of radiation therapy delivery, clinical research on treatment options, and advanced techniques in radiotherapy delivery.
There are many ongoing advances in patient treatment and immunomodulation in the context of HPV- head and neck cancer, clinical research on treatment options, and advanced techniques in immunotherapy and radiotherapy delivery.
Failure to stay informed leads to lower quality of care by practicing clinicians. By learning from this lecture, attendees will be able to narrow competency gaps for these patients. Providers need to consistently apply the latest evidence-based treatment strategies and therapeutic strategies in their clinical practice to enhance patient outcomes and personalize care for everyone.
Target Audience
This meeting was designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists, speech language pathologists/scientists, dentists, oral surgeons, swallowing and speech therapists, audiologists, physical therapists, scientists, immunologist and rehabilitation specialists.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Be informed about advances in patient safety in the context of radiation therapy delivery, clinical research on treatment options, and advanced techniques in radiotherapy delivery.
- Narrow competency gaps for these patients.
- Apply the latest evidence-based treatment strategies and therapeutic strategies in their clinical practice to enhance patient outcomes and personalize care for everyone.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.50 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.